The advantage of using 3-week data to predict response to aripiprazole at week 6 in first-episode psychosis

International Clinical Psychopharmacology

Volumn 29, Issue 2, 2014, Pages 77-85

  Park, Jong Il ^a   Cho, Dong Hwan ^b   Hahn, Sang Woo ^c   Jeong, Bumseok ^d   Kim, Jong Hoon ^e   Kim, Sung Wan ^f   Koo, Min Seong ^g   Lee, Seung Hwan ^h   Lee, Seung Jae ⁱ   Lee, Yo Han ^j   Park, Jong Ik ^k   Rho, Seung Ho ^l   Chung, Young Chul ^a  

^a Chonbuk National University Medical School   (South Korea)

^b Dr Cho's Neuropsychiatry Clinic and Research Center   (South Korea)

^c Soonchunhyang University   (South Korea)

^d Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^e Gachon University   (South Korea)

^f Chonnam National University Medical School   (South Korea)

^g Kwandong University College of Medicine   (South Korea)

^h Inje University College of Medicine   (South Korea)

ⁱ Kyungpook National University School of Medicine   (South Korea)

^j Department of Old Age Psychiatry   (South Korea)

^k Kangwon National University College of Medicine   (South Korea)

^l Wonkwang University   (South Korea)

more..

Author keywords

Aripiprazole; Early Response; Efficacy; First Episode Psychosis; Safety

Indexed keywords

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PIPERAZINES; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; QUINOLONES; REPUBLIC OF KOREA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84895077130     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0000000000000005     Document Type: Article

References (47)

1. Agid O, Kapur S, Arenovich T, Zipursky RB (2003). Delayed-onset hypothesis of antipsychotic action: A hypothesis test ed and rejected. Arch Gen Psychiatry 60:1228-1235.
2. American Psychiatric Association (1994). Diagnostic and statistical manual of mental disorders, 4th rev. Washington, DC: American Psychiatric Press.
3. Andreasen NC (1984). Scale for the assessment of positive symptoms (SAPS). Iowa City, IA: University of Iowa Press.
4. Barnes TRE (1989). A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676.
5. Berger GE, Proffitt TM, McConchie M, Kerr M, Markulev C, Yuen HP, et al. (2008). Dosing quetiapine in drug-nave first-episode psychosis: A controlled, double-blind, randomized, single- center study investigating efficacy, tolerability, and safety of 200 mg/day vs. 400 mg/day of quetiapine fumarate in 141 patients aged 15 to 25 years. J Clin Psychiatry 69:1702-1714.
6. Canuso CM, Grinspan A, Kalali A, Damaraju CV, Merriman U, Alphs L, Awad AG (2010). Medication satisfaction in schizophrenia: A blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone. Int Clin Psychopharmacol 25:155-164.
7. Chatterjee A, Chakos M, Koreen A, Geisler S, Sheitman B, Woerner M, et al. (1995). Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medic ated schizophrenic patients. Am J Psychiatry 152:1724-1729.
8. Chrzanowski WK, Marcus RN, Torbeyns A, Nyilas M, McQuade RD (2006). Effectiveness of long-term aripiprazole therapy in patients with acute ly relapsing or chronic, stable schizophrenia: A 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl) 189:259-266.
9. DeLeon A, Patel NC, Crismon ML (2004). Aripiprazole: A comprehensive r eview of its pharmacology, clinical efficacy, and tolerability. Clin Ther 26:649-666.
10. Emsley RA. The Risperidone Working Group (1999). Risperidone in the treatment of first-episode psychotic patients: A double-blin d multicenter study. Schizophr Bull 25:721-729.
11. First M, Spitzer RL, Gibbon M (1997). Structured clinical interview for DSM-IV Axis I disorders - patient edition. New York, NY: Biometrics Research Depa rtment, New York State Psychiatric Institute.
12. Guy W (1976). ECDEU assessment manual for psychopharmacology, revised. Rockville, MD: National Institute of Mental Health.
13. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al. (2008). Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: An open randomized clinical trial. Lancet 371:1085-1097.
14. Kampman O, Laippala P, Vaananen J, Koivisto E, Kiviniemi P, Kilkku N, et al. (2002). Indicators of medication compliance in first-episode psychosis. Psychiatry Res 110:39-48.
15. Kane JM, Carson WH, Saha AR, Mcquade RD, Ingenito GG, Zimbroff DL, et al. (2002). Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiat ry 63:763-771.
16. Kane JM, FleischhackerWW, Hansen L, Perlis R, Pikalov A III, Assunça o-Talbott S, et al. (2009). Akathisia: An updated review focusing on second-generation antipsychotics. J Clin Psychiatry 70:627-643.
17. Kay SR, Fiszbein A, Opler LA (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276.
18. Lea JW, Stoner SC, Lafollette J (2007). Agitation associated with aripiprazole initiation. Pharmacotherapy 27:1339-1342.
19. Lee HY, Ham BJ, Kang RH, Paik JW, Hahn SW, Lee MS, e t al. (2010). Trial of aripiprazole in the treatment of first-episode schizophrenia. Psychiatry Clin Neurosci 64:38-43.
20. Lee KH, Sakong J, Shin JH, Han YH (2009). Aripiprazole effects in patients wi th acute schizophrenia experiencing higher or lower agitation. J Korean Neuropsychiatr Assoc 48:320-327.
21. Leucht S, Busch R, Hamann J, Kissling W, Kane JM (2005a ). Early-onset hypothesis of antipsychotic drug action: A hypothesis tested, confirmed and extended. Biol Psychiatry 57:1543-1549.
22. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR (2005b ). What does the PANSS mean Schizophr Res 79:231-238.
23. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009a ). Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis. Lancet 373:31-41.
24. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, et al. (2009b ). A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 166: 152-163.
25. Leucht S, Kissling W, Davis JM (2010). The PANSS should be rescaled. Schizophr Bull 36:461-462.
26. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, et al. (2003). Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: A randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 160:1396-1404.
27. Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, et al. (2003). Aripiprazole in the treatment of schizophrenia: Safety and tolerability in short-term, p lacebo-controlled trials. Schizophr Res 61:123-136.
28. Marder SR, West B, Lau GS, Pultz JA, Pikalov A, Marcus RN, et al. (2007). Aripiprazole effects in patients with acute schizophrenia experi encing higher or lower agitation: A post hoc analysis of 4 randomized, placebo-controlled clinical trials. J Clin Psychiatry 68:662-668.
29. McCue RE, Waheed R, Urcuyo L, Orendain G, Joseph MD, Charles R, et al. (2006). Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. Br J Psychiatry 189:433-440.
30. McGrath J, Saha S, Chant D, Welham J (2008). Schizophrenia: A concise overview of incidence, prevalence, and mortality. Epidemiol Rev 30:67-76.
31. Moller HJ, Riedel M, Jager M, Wickelmaier F, Maier W, Kuhn KU, et al. (2008). Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. Int J Neuropsychopharmacol 11:985-997.
32. Myrtek M, Foerster F (1986). The law of initial value: A rare exception. Biol Psychol 22:227-237.
33. Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito G G. Aripiprazole Study Group (2003). Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: A placebo-controlled 26-week study. J Clin Psychiatry 64:1048-1056.
34. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, et al. (2003). Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs. placebo in patients with schizophrenia and schizoaffecti ve disorder. Arch Gen Psychiatry 60:681-690.
35. Robinson DG, Woerner MG, Alvir JM Junior, Bilder RM, Hinrichsen GA, Lieberman JA (2002). Predictors of medication discontinuation by patients with fi rst-episode schizophrenia and schizoaffective disorder. Schizophr Res 57:209-219.
36. Safer DJ (2004). A comparison of risperidone-induced weight gain across the age span. J Clin Psychopharmacol 24:429-436.
37. Sanger TM, Lieberman JA, Tohen M, Grundy S, Beasley C Jr, Tollefson GD (1999). Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry 156:79-87.
38. Schennach-Wolff R, Seemuller FH, Mayr A, Conley R, Ascher-Svanum H, Kollack-Walker S, et al. (2010). An early improvement threshold to predict response and remission in first-episode schizophrenia. Br J Psychiatry 196:460-466.
39. Schennach-Wolff R, Jager M, Mayr A, Meyer S, Kuhn KU, Klingberg S, et al. (2011). Predictors of response and remission in the acute treatment of firstepisode schizophrenia patients - is it all about early response Eur Neuropsychopharmacol 21:370-378.
40. Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, et al. (2005). Risperidone and haloperidol in first-episode psychosis: A long-term ran domized trial. Am J Psychiatry 162:947-953.
41. Simpson GM, Angus JW (1970). A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212 (Suppl 44):11-19.
42. Stassen HH, Angst J (1998). Delayed onset of action of antidepressants. CNS drugs 9:177-184.
43. Stauffer VL, Case M, Kinon BJ, Conley R, Ascher-Svanum H, Kollack-Walker S, et al. (2011). Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis. Psychiatry Res 187:42-48.
44. Takahashi H, Oshimo T, Ishigooka J (2009). Efficacy and tolerability of aripiprazole in first-episode drug-nave patients with schizophrenia: An open-label trial. Clin Neuropharmacol 32:149-150.
45. Thone J (2007). Worsened agitation and confusion in schizophrenia subsequent to high-dose aripiprazole. J Neuropsychiatry Clin Neurosci 19:481-482.
46. Yap HL, Mahendran R, Lim D, Liow PH, Lee A, Phang S, et al. (20 01). Risperidone in the treatment of first episode psychosis. Singapore Med J 42:170-173.
47. Zimbroff D, Warrington L, Loebel A, Yang R, Siu C (2007). Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: A randomized, double-blind, 4-week study. Int Clin Psychopharmacol 22:363-370.